Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

Post time 2024-6-4 21:31:34

journal：New England Journal of Medicine

Authors：Meletios Athanasios Dimopoulos; Meral Beksac; Ludek Pour; Sosana Delimpasi; Vladimir Vorobyev; Hang Quach; Ivan Spicka; Jakub Radocha; Pawel Robak; Kihyun Kim; Michele Cavo; Kazuhito Suzuki; Kristin Morris; Farrah Pompilus; Amy Phillips-Jones; Xiaoou L. Zhou; Giulia Fulci; Neal Sule; Brandon E. Kremer; Joanna Opalinska; María-Victoria Mateos; Suzanne Trudel

Published date：--

DOI：10.1056/nejmoa2403407

PDF link：http://www.nejm.org/doi/pdf/10.1056/NEJMoa2403407

Article link：http://dx.doi.org/10.1056/nejmoa2403407

Article Source：Massachusetts Medical Society。

Remark：

Post time 2024-6-4 21:31:35

: This post has been completed
Completed attachments will be deleted within 24 hours.

[NEJM] Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[NEJM] Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[NEJM] Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma